MCID: MNC007
MIFTS: 53

Monocytic Leukemia

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Monocytic Leukemia

MalaCards integrated aliases for Monocytic Leukemia:

Name: Monocytic Leukemia 12 54 15 71
Monocytic Leukaemia 12 32
M5b Acute Differentiated Monocytic Leukemia 71
Schilling's Leukaemia 12
Schilling's Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8527
ICD9CM 34 206.8
ICD10 32 C93 C93.9 C93.Z
UMLS 71 C0153903 C0598894 C1318544

Summaries for Monocytic Leukemia

Disease Ontology : 12 A myeloid leukemia that is characterized by a dominance of monocytes in the marrow.

MalaCards based summary : Monocytic Leukemia, also known as monocytic leukaemia, is related to leukemia, acute monocytic and acute monoblastic leukemia. An important gene associated with Monocytic Leukemia is KAT6A (Lysine Acetyltransferase 6A), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cyclophosphamide and Mesna have been mentioned in the context of this disorder. Affiliated tissues include monocytes, myeloid and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Monocytic Leukemia

Diseases in the Monocytic Leukemia family:

Leukemia, Acute Monocytic Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Monocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 666)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute monocytic 33.6 TNF KMT2A KAT6A IL6 IL1B CXCL8
2 acute monoblastic leukemia 33.6 KMT2A IL6 CXCL8 CSF2
3 histiocytosis 31.1 TNF IFNG CSF2
4 chronic myelomonocytic leukemia 31.0 KMT2A KAT6A CSF2 CSF1
5 myeloid leukemia 30.9 KMT2A KAT6A ITGAM CSF2 CD14
6 langerhans cell histiocytosis 30.8 IFNG CSF2 CSF1
7 purpura 30.3 TNF IL6 IFNG
8 chickenpox 30.2 TNF IL6 IFNG
9 herpangina 30.2 TNF IL6 IFNG
10 splenic disease 30.2 TNF IL6 IFNG
11 leukostasis 30.2 TNF IL6 IL1B
12 pancytopenia 30.2 KMT2A IL6 IFNG CSF2 CSF1
13 obstructive jaundice 30.1 TNF IL6 CXCL8
14 severe combined immunodeficiency 30.1 JUN IL6 IFNG CSF2 CSF1 CASP3
15 pulmonary tuberculosis 30.0 TNF IL6 IL1B IFNG
16 crohn's colitis 30.0 TNF IL1B IFNG CXCL8
17 severe congenital neutropenia 30.0 TNF IL1B CSF2 CSF1
18 endocarditis 30.0 TNF IL6 IFNG CXCL8
19 gastric ulcer 30.0 TNF IL6 IL1B CXCL8
20 visceral leishmaniasis 30.0 TNF IL1B IFNG CXCL8
21 graft-versus-host disease 30.0 TNF IL6 IL1B IFNG FAS
22 respiratory failure 30.0 TNF JUN IL6 IL1B CXCL8
23 bone resorption disease 30.0 TNF PPARG IL6 IL1B CSF1
24 acute pancreatitis 30.0 TNF IL6 IL1B CXCL8
25 cholera 30.0 TNF IL6 IL1B CXCL8
26 leukemia, chronic lymphocytic 29.9 TNF KMT2A IL6 FAS CSF2 CASP3
27 allergic hypersensitivity disease 29.9 TNF IFNG CXCL8 CSF2
28 gingivitis 29.9 TNF IL6 IL1B IFNG CXCL8
29 sarcoidosis 1 29.9 TNF ITGAM IL1B IFNG
30 pertussis 29.9 TNF JUN ITGAM IL6 IL1B CXCL8
31 hemophagocytic lymphohistiocytosis 29.9 TNF IFNG FAS CXCL8
32 bone disease 29.9 TNF IL6 IL1B CXCL8 CSF1
33 hypereosinophilic syndrome 29.9 IFNG CYSLTR1 CXCL8 CSF2
34 neuritis 29.8 TNF IL6 IL1B IFNG CXCL8
35 ileus 29.8 TNF IL6 IL1B IFNG CSF2
36 nervous system disease 29.8 TNF IL6 IL1B IFNG CSF2
37 amyloidosis 29.8 TNFRSF1A TNF IL6 IL1B
38 exanthem 29.8 TNF IL6 IL1B IFNG CXCL8 CSF2
39 cytomegalovirus infection 29.8 TNF IL6 IL1B FAS CXCL8 CASP3
40 t-cell lymphoblastic leukemia/lymphoma 29.8 TNFRSF1A JUN FAS CASP3
41 sarcoma 29.8 TNFRSF1A JUN IL6 FAS CXCL8 CSF2
42 mycobacterium tuberculosis 1 29.8 TNFRSF1A TNF ITGAM IFNG
43 hematologic cancer 29.7 TNF KMT2A IL6 CSF2 CSF1 CASP3
44 gingival overgrowth 29.7 TNF IL6 CXCL8
45 essential thrombocythemia 29.7 TNF ITGAM IL6 CXCL8 CSF2
46 myelofibrosis 29.6 TNF ITGAM IL1B CXCL8
47 central nervous system disease 29.6 TNF IL6 IL1B IFNG
48 meningitis 29.6 TNF IL6 IL1B IFNG CXCL8 CSF2
49 candidiasis 29.6 TNF IL6 IL1B IFNG CXCL8 CSF2
50 crohn's disease 29.5 TNFRSF1A TNF IL6 IL1B IFNG CXCL8

Graphical network of the top 20 diseases related to Monocytic Leukemia:



Diseases related to Monocytic Leukemia

Symptoms & Phenotypes for Monocytic Leukemia

GenomeRNAi Phenotypes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.55 CASP3 CD14 CXCL8 FAS IL1B JUN
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.55 CASP3 CD14 CXCL8 FAS IL1B JUN
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.55 JUN
4 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.26 CASP3 CSF2 CXCL8 TNF

MGI Mouse Phenotypes related to Monocytic Leukemia:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.47 CAB39L CASP3 CSF1 CSF2 CYSLTR1 FAS
2 hematopoietic system MP:0005397 10.45 CAB39L CASP3 CD14 CSF1 CSF2 FAS
3 cellular MP:0005384 10.43 CASP3 CSF1 CSF2 CYSLTR1 FAS IFNG
4 immune system MP:0005387 10.43 CASP3 CD14 CSF1 CSF2 CYSLTR1 FAS
5 homeostasis/metabolism MP:0005376 10.41 CASP3 CD14 CSF1 CSF2 FAS IFNG
6 growth/size/body region MP:0005378 10.4 CASP3 CD14 CSF1 CSF2 FAS IFNG
7 behavior/neurological MP:0005386 10.38 CASP3 CSF1 CSF2 FAS IFNG IL6
8 mortality/aging MP:0010768 10.35 CASP3 CD14 CSF1 CSF2 FAS IFNG
9 integument MP:0010771 10.32 CASP3 CSF1 CSF2 FAS IFNG IL1B
10 endocrine/exocrine gland MP:0005379 10.31 CASP3 CSF1 CSF2 FAS IFNG IL6
11 craniofacial MP:0005382 10.27 CASP3 CSF1 CSF2 FAS IFNG IL1B
12 nervous system MP:0003631 10.25 CASP3 CSF1 CSF2 FAS IFNG IL1B
13 liver/biliary system MP:0005370 10.19 CSF1 FAS IFNG IL6 JUN KAT6A
14 muscle MP:0005369 10.11 CASP3 CSF1 FAS IFNG IL6 KMT2A
15 neoplasm MP:0002006 10.09 CSF2 FAS IFNG IL1B IL6 KMT2A
16 reproductive system MP:0005389 10 CASP3 CSF1 CSF2 FAS IFNG IL6
17 no phenotypic analysis MP:0003012 9.97 CASP3 CSF1 IFNG JUN KMT2A PPARG
18 renal/urinary system MP:0005367 9.92 CASP3 CSF2 FAS IFNG IL6 KMT2A
19 respiratory system MP:0005388 9.9 CASP3 CD14 CSF1 CSF2 CYSLTR1 FAS
20 skeleton MP:0005390 9.8 CASP3 CD14 CSF1 CSF2 FAS IFNG
21 vision/eye MP:0005391 9.28 CASP3 CSF1 FAS IFNG IL6 JUN

Drugs & Therapeutics for Monocytic Leukemia

Drugs for Monocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
2
Mesna Approved, Investigational Phase 3 3375-50-6 598
3
Idarubicin Approved Phase 3 58957-92-9 42890
4
leucovorin Approved Phase 3 58-05-9 6006 143
5
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
6
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
7
Lenograstim Approved, Investigational Phase 3 135968-09-1
8
Etoposide Approved Phase 3 33419-42-0 36462
9
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
10
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
11
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
12
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
13
Arsenic trioxide Approved, Investigational Phase 2, Phase 3 1327-53-3 518740
14
Fludarabine Approved Phase 2, Phase 3 21679-14-1, 75607-67-9 30751
15
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
16
Thioguanine Approved Phase 3 154-42-7 2723601
17
Melphalan Approved Phase 3 148-82-3 460612 4053
18
Carmustine Approved, Investigational Phase 3 154-93-8 2578
19
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
20
Hydroxyurea Approved Phase 3 127-07-1 3657
21
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
22
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
23
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
24
Daunorubicin Approved Phase 3 20830-81-3 30323
25
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
27
midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
28
Histamine Approved, Investigational Phase 3 51-45-6 774
29
Cyproheptadine Approved Phase 3 129-03-3 2913
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
31
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
32 Lintuzumab Investigational Phase 3 166089-32-3
33 Molgramostim Investigational Phase 3 99283-10-0
34
tipifarnib Investigational Phase 2, Phase 3 192185-72-1 159324
35 Vaccines Phase 3
36 Immunoglobulins Phase 3
37 Antibodies Phase 3
38 Antibodies, Monoclonal Phase 3
39 Gemtuzumab Phase 3
40 Antineoplastic Agents, Immunological Phase 3
41 Folic Acid Antagonists Phase 3
42 Vitamin B Complex Phase 3
43 Alkylating Agents Phase 2, Phase 3
44 Folate Phase 3
45 Antirheumatic Agents Phase 3
46 Vitamin B9 Phase 3
47 Etoposide phosphate Phase 3
48 Protective Agents Phase 3
49 Radiation-Protective Agents Phase 3
50 Analgesics Phase 3

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study Unknown status NCT00454168 Phase 3
2 Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
3 Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute Myelogenous Leukemia (AML) Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
4 The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
5 RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
6 ACUTE MYELOID LEUKAEMIA TRIAL 12 Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
7 A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission Completed NCT00006223 Phase 3
8 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
9 A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse Completed NCT00112554 Phase 3 cytarabine;laromustine
10 High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
11 RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL) Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
12 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
13 Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
14 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
15 A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML) Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
16 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
17 Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
18 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
19 A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
20 A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
21 A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
22 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
23 Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
24 Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
25 Phase II, Open-Label Study of HuM195 (Humanized Anti-CD33 Monoclonal Antibody) Administered to Patients With Acute Myelogenous Leukemia (AML) Who Are Documented Regimen Failures (RF) of the Control Arm of Study 195-301 Unknown status NCT00006084 Phase 2
26 A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
27 Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial) Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
28 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
29 Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study Completed NCT00004899 Phase 2 busulfan;etoposide
30 Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML) Completed NCT00528398 Phase 2 cytarabine;idarubicin
31 Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients Greater Than or Equal to 65 Years Old Completed NCT00005795 Phase 2 arsenic trioxide
32 PHASE II STUDY EVALUATING AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR ACUTE LEUKEMIAS Completed NCT00002567 Phase 2 etoposide
33 5-Azacytidine to Treat Acute Myeloid Leukemia in Elderly or Frail Patients Not Suitable for Intensive Chemotherapy. A Multicenter Phase II Trial. Completed NCT00739388 Phase 2 azacytidine
34 A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia Completed NCT01656031 Phase 2 clofarabine;cytarabine
35 A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML Completed NCT00425477 Phase 2 bexarotene
36 A Phase II Trial Combining Gemtuzumab Ozogamicin (Mylotarg) With Cyclosporine for the Treatment of Relapsed Acute Myeloid Leukemia in Adults Over Age 60 Completed NCT00089050 Phase 2 cyclosporine;gemtuzumab ozogamicin
37 Pilot Study of Sodium Phenylbutyrate Plus Azacytidine Completed NCT00006019 Phase 2 azacitidine;sodium phenylbutyrate
38 A Phase II Study of Allografting to Establish Mixed or Full Donor Chimerism as Consolidative Immunotherapy for Older Patients With AML in Complete Remission Using Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00005801 Phase 2
39 Phase II Study of High-Dose Busulfan and Cyclophosphamide Followed by Allogeneic Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia Completed NCT00004896 Phase 2 busulfan;cyclophosphamide
40 A Phase II Study Of Daunomycin And ARA-C, Both Given By Continous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older Completed NCT00023777 Phase 2 cytarabine;daunorubicin hydrochloride
41 Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia: A POG Phase II Study Completed NCT00003178 Phase 2 cladribine;idarubicin
42 A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg) and Standard Dose ARA-C for Patients With Relapsed Acute Myeloid Leukemia (AML) Completed NCT00049179 Phase 2 cytarabine;gemtuzumab ozogamicin
43 A Phase I/II Study of CLOLAR® (Clofarabine, IND# 73, 789) in Combination With Cytarabine in Pediatric Patients With Refractory/Relapsed Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
44 Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myelogenous Leukemia in Remission Using HLA-Matched Sibling Donors, HLA-Matched Unrelated Donors, or HLA-Mismatched Familial Donors - A Phase 2 Study Completed NCT01020734 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate
45 ALLOGENEIC AND SYNGENEIC MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA Completed NCT00002547 Phase 2 busulfan;cyclophosphamide;cyclosporine;cytarabine;methotrexate
46 An Open Label Phase II Trial of Clofarabine and Temsirolimus in Older Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Completed NCT00775593 Phase 2 clofarabine;temsirolimus
47 Gemtuzumab Ozogamicin (CMA-676) Followed or Not by Intensive Chemotherapy as Initial Treatment for Elderly Patients With Acute Myeloid Leukemia: An EORTC-LG Pilot Phase II Study Completed NCT00006122 Phase 2 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
48 A Phase II Randomized Trial of Immunologic and Chemotherapeutic Agents for Treatment of Patients With Relapsed or Refractory Acute Myelogenous Leukemia Completed NCT00005962 Phase 2 cyclophosphamide;cytarabine;gemtuzumab ozogamicin;liposomal daunorubicin citrate;topotecan hydrochloride
49 A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide (DATE) for De Novo AML: In the Treatment of Young Patients Ages 16-59 Completed NCT00005793 Phase 1, Phase 2 Cytarabine;Daunorubicin;Etoposide;Topotecan
50 A Phase II Study of Daunomycin and ARA-C Given by Continuous IV Infusion With PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older Completed NCT00004217 Phase 2 cytarabine;daunorubicin hydrochloride;valspodar

Search NIH Clinical Center for Monocytic Leukemia

Genetic Tests for Monocytic Leukemia

Anatomical Context for Monocytic Leukemia

MalaCards organs/tissues related to Monocytic Leukemia:

40
Monocytes, Myeloid, Bone, Bone Marrow, Skin, Endothelial, T Cells

Publications for Monocytic Leukemia

Articles related to Monocytic Leukemia:

(show top 50) (show all 2240)
# Title Authors PMID Year
1
Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent. 61 54
20427734 2010
2
The FGL2/fibroleukin prothrombinase is involved in alveolar macrophage activation in COPD through the MAPK pathway. 61 54
20438701 2010
3
Effect of Sargassum thunbergii on ROS mediated oxidative damage and identification of polyunsaturated fatty acid components. 54 61
20171254 2010
4
A mathematical model to derive N-glycan structures and cellular enzyme activities from mass spectrometric data. 54 61
19506293 2009
5
Anti-moesin antibodies derived from patients with aplastic anemia stimulate monocytic cells to secrete TNF-alpha through an ERK1/2-dependent pathway. 61 54
19556303 2009
6
Antiglaucoma drug GLC756 and its effect on cellular cAMP and tumor necrosis factor alpha release in vitro of activated human monocytic leukemia cells. 61 54
19333701 2009
7
Cysteinyl leukotrienes induce monocyte chemoattractant protein-1 in human monocyte/macrophages via mitogen-activated protein kinase and nuclear factor-kappaB pathways. 61 54
19218821 2009
8
Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique. 54 61
18528428 2008
9
Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the peroxisome proliferator-activated receptor gamma. 61 54
17870167 2008
10
LPS-induced Toll-like receptor 4 signalling triggers cross-talk of apoptosis signal-regulating kinase 1 (ASK1) and HIF-1alpha protein. 61 54
18155167 2008
11
A new simple multi-well plate-based assay for monocyte differentiation using human monocytic leukemia THP-1 cells. 54 61
17920620 2007
12
MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells. 54 61
17694082 2007
13
LRP16 is fused to RUNX1 in monocytic leukemia cell line with t(11;21)(q13;q22). 54 61
17532767 2007
14
Hydrolyzed metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity. 61 54
17409565 2007
15
Plasma level of stromal derived factor-1 (SDF-1) is increased in disseminated intravascular coagulation patients who have poor outcomes: in vitro effect of SDF-1 on coagulopathy. 61 54
17239427 2007
16
Mono- and dihydroxylated metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity. 61 54
17139107 2006
17
Rolling and adhesion of apoptotic monocytes is impaired by loss of functional cell surface-expressed P-selectin glycoprotein ligand-1. 61 54
16839361 2006
18
ST2 suppresses IL-6 production via the inhibition of IkappaB degradation induced by the LPS signal in THP-1 cells. 54 61
16426569 2006
19
[Expression of SDF-1alpha and its receptor CXCR4 in acute leukemias and their relationship with extramedullary infiltration]. 61 54
16584580 2006
20
Modulation of autocrine TNF-alpha-stimulated matrix metalloproteinase 9 (MMP-9) expression by mitogen-activated protein kinases in THP-1 monocytic cells. 54 61
16497166 2006
21
[In vitro stimulation of specific antileukemia T-cell response by dendritic cells derived from CD14+ acute monocytic leukemia cells]. 61 54
16552959 2005
22
MLL-MLLT10 fusion gene in pediatric acute megakaryoblastic leukemia. 54 61
16111539 2005
23
Cysteinyl leukotrienes induce monocyte chemoattractant protein 1 in human monocytes/macrophages. 54 61
16164450 2005
24
Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules. 54 61
15984600 2005
25
Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. 61 54
15767555 2005
26
Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. 54 61
15680279 2005
27
Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF. 54 61
15313893 2004
28
Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation. 61 54
15016631 2004
29
Proteasome inhibitors modulate chemokine production in lung epithelial and monocytic cells. 54 61
15293603 2004
30
Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. 61 54
12738674 2003
31
Regulation of A + U-rich element-directed mRNA turnover involving reversible phosphorylation of AUF1. 54 61
12819195 2003
32
A synergistic increase of apoptosis utilizing Fas antigen expression induced by low doses of anticancer drug. 61 54
13677932 2003
33
The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. 61 54
12761814 2003
34
Differential effect of Bcl-xl over-expression on cell death of the monocytic leukemia cell line U937. 54 61
12553012 2002
35
Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. 61 54
12003967 2002
36
MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2. 54 61
11965546 2002
37
WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. 54 61
11861382 2002
38
PPARgamma ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells. 54 61
11861425 2002
39
Regulation of gelatinase B in human monocytic and endothelial cells by PECAM-1 ligation and its modulation by interferon-beta. 61 54
11781384 2002
40
Augmented expression of P-gp/multi-drug resistance gene by all-trans retinoic acid in monocytic leukemic cells. 61 54
11734301 2002
41
Identification of LIL-STAT in monocytic leukemia cells and monocytes after stimulation with interleukin-6 or interferon gamma. 61 54
11739196 2001
42
Histamine increases the expression of LOX-1 via H2 receptor in human monocytic THP-1 cells. 61 54
11728449 2001
43
Effect of trapidil on effector functions of monocytes related to atherosclerotic plaque. 54 61
11689197 2001
44
Apoptosis induction by epigallocatechin gallate involves its binding to Fas. 61 54
11478767 2001
45
Effect of unique Mycobacterium leprae phenolic glycolipid-I (PGL-I) on tumour necrosis factor production by human mononuclear cells. 54 61
11355520 2001
46
Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. 61 54
11243405 2001
47
MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). 61 54
10824998 2000
48
Resveratrol induces Fas signalling-independent apoptosis in THP-1 human monocytic leukaemia cells. 54 61
10848832 2000
49
Priming effects of macrophage colony-stimulating factor on monocytic leukemia cells in combination with chemotherapy: induction of programmed cell death in vivo. 61 54
10784404 2000
50
Inhibition of the mitogen activated protein kinase pathway potentiates radiation-induced cell killing via cell cycle arrest at the G2/M transition and independently of increased signaling by the JNK/c-Jun pathway. 61 54
10639586 2000

Variations for Monocytic Leukemia

Expression for Monocytic Leukemia

Search GEO for disease gene expression data for Monocytic Leukemia.

Pathways for Monocytic Leukemia

Pathways related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 113)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.14 TNFRSF1A TNF JUN ITGAM IL6 IL1B
2
Show member pathways
13.96 TNFRSF1A TNF JUN ITGAM IL6 IL1B
3
Show member pathways
13.81 TNFRSF1A TNF JUN IL6 IL1B IFNG
4
Show member pathways
13.63 TNFRSF1A TNF JUN ITGAM IL6 IL1B
5
Show member pathways
13.55 TNFRSF1A TNF ITGAM IL6 IL1B FAS
6
Show member pathways
13.5 TNFRSF1A TNF ITGAM IL6 IL1B IFNG
7
Show member pathways
13.44 TNFRSF1A TNF PPARG JUN IL6 IL1B
8
Show member pathways
13.44 TNFRSF1A TNF JUN IL6 IL1B FAS
9
Show member pathways
13.31 TNFRSF1A TNF PPARG IL6 IL1B FAS
10
Show member pathways
13.18 TNFRSF1A TNF JUN IL6 IL1B IFNG
11
Show member pathways
13.1 TNFRSF1A TNF JUN IL6 IL1B FAS
12
Show member pathways
13.09 TNFRSF1A TNF IL6 FAS CSF1 CASP3
13
Show member pathways
13.01 TNF IL6 IL1B IFNG FAS CXCL8
14 13 PPARG JUN IL6 IFNG FAS CXCL8
15
Show member pathways
12.99 PPARG JUN ITGAM CSF2 CD14 CASP3
16 12.95 TNFRSF1A TNF IL6 IL1B IFNG FAS
17
Show member pathways
12.95 TNFRSF1A TNF JUN IL6 IL1B IFNG
18 12.93 TNFRSF1A TNF JUN IL1B FAS CSF1
19
Show member pathways
12.87 TNF JUN IL6 IL1B CXCL8 CD14
20
Show member pathways
12.83 TNFRSF1A TNF JUN IL1B IFNG FAS
21
Show member pathways
12.82 TNFRSF1A TNF JUN ITGAM FAS CASP3
22
Show member pathways
12.8 TNFRSF1A TNF JUN FAS CASP3
23
Show member pathways
12.77 TNF JUN IL6 IL1B IFNG FAS
24
Show member pathways
12.75 TNFRSF1A TNF JUN IL1B FAS CASP3
25
Show member pathways
12.71 TNF JUN IL6 IL1B IFNG
26
Show member pathways
12.7 TNF IL6 IL1B IFNG CD14
27 12.68 TNFRSF1A TNF IL1B IFNG FAS
28
Show member pathways
12.68 TNF JUN IFNG FAS CSF2 CASP3
29 12.59 TNFRSF1A TNF JUN IL1B CXCL8 CSF2
30 12.5 TNFRSF1A TNF JUN IL6 CSF2
31
Show member pathways
12.5 TNF JUN IL6 IL1B IFNG CXCL8
32
Show member pathways
12.5 TNF JUN IL6 IL1B IFNG CXCL8
33
Show member pathways
12.49 TNFRSF1A TNF IL6 CXCL8 CSF1
34
Show member pathways
12.49 TNF IL6 IL1B IFNG CSF1
36 12.46 TNFRSF1A TNF JUN IL6 IL1B CXCL8
37 12.44 PPARG KMT2A ITGAM IL6 CXCL8 CSF2
38
Show member pathways
12.43 TNFRSF1A TNF JUN ITGAM IL1B IFNG
39
Show member pathways
12.42 TNF JUN IL6 CXCL8 CD14
40 12.42 TNFRSF1A TNF JUN IL6 IL1B FAS
41 12.4 TNF JUN IL6 IL1B CXCL8
42
Show member pathways
12.38 TNF IL6 IL1B IFNG CXCL8
43
Show member pathways
12.38 TNFRSF1A TNF JUN FAS CASP3
44
Show member pathways
12.37 TNFRSF1A TNF IL1B IFNG FAS
45 12.37 TNFRSF1A TNF ITGAM IL6 IL1B IFNG
46 12.36 TNF JUN IL6 IL1B CXCL8 CASP3
47 12.35 TNFRSF1A TNF FAS CASP3
48 12.35 TNFRSF1A TNF IL6 IFNG CASP3
49
Show member pathways
12.32 TNF JUN IL6 IL1B
50 12.31 TNFRSF1A TNF IL1B FAS CASP3

GO Terms for Monocytic Leukemia

Cellular components related to Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 TNFRSF1A TNF KIAA0100 IL6 IL1B IFNG
2 extracellular space GO:0005615 9.65 TNFRSF1A TNF ITGAM IL6 IL1B IFNG
3 MOZ/MORF histone acetyltransferase complex GO:0070776 9.32 KAT6B KAT6A
4 death-inducing signaling complex GO:0031264 9.26 FAS CASP3
5 membrane raft GO:0045121 9.1 TNFRSF1A TNF ITGAM FAS CD14 CASP3

Biological processes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.15 TNFRSF1A TNF PPARG KMT2A KAT6B KAT6A
2 positive regulation of cell proliferation GO:0008284 10.14 JUN IL6 IL1B IFNG CSF2 CSF1
3 apoptotic process GO:0006915 10.14 TNFRSF1A KMT2A IL1B IFNG FAS CD14
4 negative regulation of cell proliferation GO:0008285 10.12 PPARG JUN IL6 IL1B CXCL8
5 positive regulation of gene expression GO:0010628 10.12 TNF IL6 IL1B IFNG CSF2 CSF1
6 negative regulation of transcription, DNA-templated GO:0045892 10.08 TNF PPARG KAT6B KAT6A JUN IFNG
7 positive regulation of apoptotic process GO:0043065 10.03 TNF PPARG JUN IL6 FAS CASP3
8 positive regulation of transcription, DNA-templated GO:0045893 10.03 TNF PPARG KMT2A KAT6B KAT6A JUN
9 immune response GO:0006955 10.02 TNF IL6 IL1B IFNG FAS CXCL8
10 positive regulation of protein phosphorylation GO:0001934 10.01 TNF IL1B IFNG FAS
11 response to lipopolysaccharide GO:0032496 10 JUN IL1B CD14 CASP3
12 defense response GO:0006952 9.99 TNFRSF1A TNF CYSLTR1 CXCL8
13 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 TNF PPARG IL6 IL1B
14 inflammatory response GO:0006954 9.95 TNFRSF1A TNF IL6 IL1B CXCL8 CSF1
15 positive regulation of inflammatory response GO:0050729 9.92 TNFRSF1A TNF IL1B IFNG
16 cellular response to mechanical stimulus GO:0071260 9.91 TNFRSF1A IL1B FAS
17 response to organic substance GO:0010033 9.91 TNF PPARG JUN CASP3
18 regulation of insulin secretion GO:0050796 9.9 TNF IL1B IFNG
19 cellular response to organic cyclic compound GO:0071407 9.9 TNF IL1B CASP3
20 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.9 TNFRSF1A TNF CD14
21 response to glucocorticoid GO:0051384 9.9 TNF IL6 CASP3
22 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.89 TNF IL1B CD14
23 positive regulation of smooth muscle cell proliferation GO:0048661 9.89 TNF JUN IL6
24 humoral immune response GO:0006959 9.88 TNF IL6 IFNG
25 positive regulation of neuron apoptotic process GO:0043525 9.88 TNF JUN CASP3
26 positive regulation of interleukin-6 production GO:0032755 9.88 TNF IL6 IL1B
27 positive regulation of phagocytosis GO:0050766 9.87 TNF IL1B IFNG
28 positive regulation of interferon-gamma production GO:0032729 9.86 TNF IL1B CD14
29 extrinsic apoptotic signaling pathway GO:0097191 9.86 TNF IFNG FAS
30 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF IL1B IFNG
31 positive regulation of interleukin-6 secretion GO:2000778 9.85 TNF IL1B IFNG
32 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.85 TNF PPARG JUN
33 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.84 TNF IL1B CSF2
34 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.84 IL1B FAS CASP3
35 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 TNF IL1B CD14
36 positive regulation of cytokine secretion GO:0050715 9.83 TNF IFNG CD14
37 negative regulation of neurogenesis GO:0050768 9.81 TNF IL6 IL1B
38 positive regulation of osteoclast differentiation GO:0045672 9.8 TNF IFNG CSF1
39 cellular response to lipopolysaccharide GO:0071222 9.8 TNF IL6 IL1B CXCL8 CSF2 CD14
40 macrophage differentiation GO:0030225 9.78 IFNG CSF2 CSF1
41 positive regulation of amyloid-beta formation GO:1902004 9.77 TNF IFNG CASP3
42 positive regulation of glial cell proliferation GO:0060252 9.76 TNF IL6 IL1B
43 astrocyte activation GO:0048143 9.75 TNF IL1B IFNG
44 positive regulation of monocyte differentiation GO:0045657 9.74 JUN CSF1
45 response to molecule of bacterial origin GO:0002237 9.74 CXCL8 CD14
46 monocyte differentiation GO:0030224 9.74 PPARG JUN CSF2
47 negative regulation of amyloid-beta clearance GO:1900222 9.73 TNF IFNG
48 negative regulation of lipid storage GO:0010888 9.73 TNF IL6
49 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.73 TNF IFNG
50 necroptotic signaling pathway GO:0097527 9.72 TNF FAS

Molecular functions related to Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 TNFRSF1A TNF PPARG KMT2A KIAA0100 KAT6B
2 transcription regulatory region DNA binding GO:0044212 9.62 TNF PPARG KMT2A JUN
3 H4 histone acetyltransferase activity GO:0010485 9.26 KAT6B KAT6A
4 cytokine activity GO:0005125 9.17 TNF IL6 IL1B IFNG CXCL8 CSF2
5 tumor necrosis factor-activated receptor activity GO:0005031 9.16 TNFRSF1A FAS

Sources for Monocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....